Carisma Therapeutics

Founded in Philadelphia, Carisma Therapeutics is dedicated to revolutionizing cancer treatment through the development of CAR-Macrophages. The company leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy to create innovative treatments for human diseases. Their core mission is to harness the power of the immune system to combat cancer, with a vision to provide groundbreaking therapies that improve patient outcomes globally.

Notable figures affiliated with Carisma Therapeutics include leading scientists and industry experts in immunotherapy and cellular therapy. The company has attracted significant investment from prominent biotech investors, enabling it to advance its research and development efforts. Key achievements include the initiation of a Phase I trial for CAR Monocytes targeting HER2-positive cancers, positioning Carisma as a pioneer in the next frontier of immunotherapy. Their work has the potential to significantly impact cancer treatment paradigms and improve survival rates for patients worldwide.